{"schema_version":"secwatch.filing_event.v1","accession":"0001607062-22-000669","form_type":"8-K","ticker":"RGBP","cik":"0001589150","company_name":"Regen BioPharma Inc","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.305184+00:00","generated_at":"2026-06-21T20:15:21.420992+00:00","sec_items":["5.03","8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Regen Biopharma increases authorized Series A Preferred shares to 739M","bullets":["Series A Preferred Stock authorized shares increased to 739,000,000 via amendment to Certificate of Designation.","Amendment to Section 1 of the Certificate of Designation effective November 3, 2022.","Company presented at Emerging Growth Conference on November 9, 2022; video available via YouTube link."],"urls":{"canonical":"https://secwatch.observer/filing/0001607062-22-000669","json":"https://secwatch.observer/filing/0001607062-22-000669.json","markdown":"https://secwatch.observer/filing/0001607062-22-000669.md","text":"https://secwatch.observer/filing/0001607062-22-000669.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1589150/000160706222000669/0001607062-22-000669-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1589150/000160706222000669/rgbp111022form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T20:15:21.420992+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}